Blood Products: Types, Storage, and Medical Uses Explained

A single blood donation doesn’t go to one patient. It gets taken apart.

Modern blood banking separates whole blood into individual components within hours of collection, each processed and stored according to its own requirements, each matched to a specific clinical need. A cancer patient needs platelets, not red cells. A trauma patient bleeding out needs plasma and red cells both. A hemophilia patient needs clotting factors, not whole blood at all.

This component approach has transformed transfusion medicine — making it safer, more efficient, and capable of serving far more patients from each donation.

Why Component Therapy Replaced Whole Blood

Whole blood transfusion was standard practice for most of the twentieth century, but it carries disadvantages that component therapy largely eliminates:

• Whole blood poses higher disease transmission risk than processed components
• Blood shortages make it wasteful to give patients what they don’t need
• Individual components have longer shelf lives when stored under their own optimal conditions
• Separation and filtration steps remove contaminants and reduce adverse reactions
• Some components can be given without strict ABO matching, expanding compatibility options

Red Blood Cell Products

Standard Red Blood Cells

The workhorse of transfusion medicine. A standard unit contains approximately 180ml of red cells in an additive preservative solution, stored at 4°C for up to 42 days.

Who receives them: Patients with symptomatic anemia that hasn’t responded to iron or vitamin therapy — hemoglobin typically below 7-8 g/dL, or higher in patients with active bleeding or heart disease. One unit raises hemoglobin by approximately 1 g/dL in a typical 155-pound adult, a predictable increment that lets clinicians dose precisely.

Washed Red Blood Cells

Washed units have most of their plasma removed through multiple saline rinse cycles. This reduces plasma proteins that trigger allergic reactions in sensitized patients.

Who receives them: Patients with recurrent, severe allergic transfusion reactions — particularly those who’ve had prior serious reactions to plasma proteins, or patients with IgA deficiency where residual plasma can cause anaphylaxis.

Leukoreduced Red Blood Cells

Filtration removes the majority of white blood cells from the unit before storage. Removing these leukocytes prevents two major complications: non-hemolytic febrile reactions (caused by cytokines released by white cells during storage) and CMV transmission (the virus hides inside white cells).

Leukoreduction is now standard practice at most U.S. blood centers for all cellular products. It also reduces the risk of HLA alloimmunization — a process where repeated transfused white cells cause recipients to develop antibodies that make future platelet transfusions less effective.

Pediatric/Divided Units

One adult donation is split into four smaller satellite bags, sized for infant transfusions. Limiting each small patient to a single donor reduces the number of donor exposures — a meaningful safety consideration for neonates receiving multiple transfusions.

Platelets

Platelet concentrates contain the cell fragments essential for clot formation, stored at room temperature with continuous gentle agitation for up to five days.

Who receives them: Patients with bleeding due to low platelet counts (thrombocytopenia) — most commonly cancer patients whose bone marrow is suppressed by chemotherapy — or patients with platelet dysfunction disorders.

An adult dose requires pooling four to six individual platelet concentrates or a single unit collected by apheresis (a process where a machine separates platelets from a donor’s blood and returns everything else). Apheresis platelets represent a full adult dose from one donor, minimizing exposure.

The five-day shelf life is the limiting constraint on platelet supply. Unlike red cells or plasma, there’s no practical way to extend it — which is why blood centers issue urgent platelet appeals and why hospitals consume their inventory rapidly.

Fresh Frozen Plasma (FFP)

FFP is plasma separated from whole blood and frozen within hours of donation, preserving all active clotting factors at near-normal concentrations. Each unit is approximately 225ml and keeps for one year at -18°C or colder.

Who receives it: Patients with documented coagulation factor deficiencies who are actively bleeding or facing invasive surgery — including those with liver disease (the liver produces most clotting factors), massive transfusion patients who’ve diluted their own factors, and patients who’ve overdosed on anticoagulants like warfarin.

FFP is not a volume expander and should not be used simply to replace lost blood volume. It carries the same infectious disease risks as other blood products and should be given only when a specific coagulation need is documented.

Cryoprecipitate (CRYO)

Cryoprecipitate is made by thawing FFP slowly at 4°C and collecting the proteins that don’t fully dissolve — a concentrated fraction rich in several specific factors.

Contents per unit: fibrinogen (factor I), factor VIII, von Willebrand factor, factor XIII, and fibronectin.

Why it matters: Cryoprecipitate is the only fibrinogen concentrate approved for intravenous use in the United States. When a patient is bleeding because their fibrinogen is depleted — from massive hemorrhage, DIC (disseminated intravascular coagulation), or liver failure — CRYO is the standard replacement product.

It’s also used to prepare fibrin glue in surgical settings, mixing CRYO with thrombin to create a biological adhesive that controls bleeding in delicate surgery where conventional sutures can’t reach.

Granulocytes

Granulocyte concentrates (primarily neutrophils) are collected by apheresis from compatible donors and transfused within 24 hours — they cannot be stored at all.

Who receives them: Patients with profound, prolonged neutropenia (usually from bone marrow failure or intensive chemotherapy) with life-threatening bacterial or fungal infections that aren’t responding to maximum antibiotic therapy.

Granulocyte transfusion is uncommon and controversial — the evidence for benefit is limited, the product is difficult to obtain, and it always requires irradiation before use to prevent graft-versus-host disease.

Clotting Factor Concentrates

Factor VIII Concentrates

Commercially prepared from pooled plasma or produced recombinantly (without human blood), Factor VIII concentrates treat hemophilia A and von Willebrand disease. Modern preparations undergo heat treatment and solvent-detergent viral inactivation, dramatically reducing the infectious disease risks that devastated the hemophilia community during the HIV crisis of the 1980s.

Recombinant Factor VIII — produced in cell cultures using genetic engineering — carries no risk of blood-borne pathogens and has become the standard of care in many countries.

Factor IX Concentrates

The equivalent treatment for hemophilia B (Christmas Disease). Purified Factor IX concentrates are preferred over older prothrombin complex concentrates, which contained additional factors that posed thrombosis risks at high doses.

Antithrombin III

Used to manage acute venous thromboembolism risk in patients with congenital antithrombin deficiency — typically during high-risk periods like surgery or prolonged immobilization, when these patients face elevated clotting risk.

Special Processing: Modified Products

CMV-Negative Components

Cytomegalovirus (CMV) lives inside white blood cells and can cause severe, life-threatening infections in immune-compromised patients — including premature infants, organ and bone marrow transplant recipients, and HIV-positive individuals.

Products from donors who have never been infected with CMV (seronegative) are reserved for these high-risk recipients. Leukoreduced products are also considered acceptable CMV-safe alternatives since removing white cells removes the viral reservoir.

Irradiated Products

Gamma radiation delivered to blood components before transfusion destroys the proliferative capacity of donor lymphocytes — preventing them from multiplying inside the recipient and attacking host tissues.

Absolute indications for irradiated blood include:

• Bone marrow and stem cell transplant recipients
• Intrauterine transfusions (fetuses)
• Patients with severe congenital immunodeficiency syndromes
• Directed donations between blood relatives

Leukoreduced Components

Filtration that removes white blood cells below accepted threshold levels protects against three distinct problems: febrile non-hemolytic reactions, CMV transmission, and HLA alloimmunization. The trade-off is a 10 to 30% reduction in platelet yield during filtration — a meaningful loss when platelets are already in short supply.

Storage Summary

These storage requirements shape everything about how blood banks operate — their equipment, their staffing, their ordering patterns, and their relationships with hospitals. Understanding them helps explain why blood shortages happen and why blood substitutes capable of room-temperature storage represent such an appealing research target.